---
title: "EMA Framework for the Qualification of Non-Mutagenic Impurities"
description: "The European Medicines Agency (EMA) has adopted a Reflection Paper on the Qualification of Non-Mutagenic Impurities (EMA/CHMP/4299/2026), introducing a new scientific framework for the safety assessment of non-mutagenic impurities in medicinal products."
url: https://qbdgroup.com/en/regulatory-updates/ema-framework-for-the-qualification-of-non-mutagenic-impurities
type: "Regulatory update"
language: en
published: 2026-02-25
author: "María José Villarroel"
category: "Regulatory Affairs"
publisher: "QbD Group"
citation: "QbD Group, \"EMA Framework for the Qualification of Non-Mutagenic Impurities\", https://qbdgroup.com/en/regulatory-updates/ema-framework-for-the-qualification-of-non-mutagenic-impurities"
---
# EMA Framework for the Qualification of Non-Mutagenic Impurities
> The European Medicines Agency (EMA) has adopted a Reflection Paper on the Qualification of Non-Mutagenic Impurities (EMA/CHMP/4299/2026), introducing a new scientific framework for the safety assessment of non-mutagenic impurities in medicinal products.

The European Medicines Agency (EMA) has adopted a **Reflection Paper on the Qualification of Non-Mutagenic Impurities (EMA/CHMP/4299/2026)**, introducing a new scientific framework for the safety assessment of non-mutagenic impurities in medicinal products. This document establishes harmonized principles to support proportionate, risk-based regulatory decision-making.

## Why is it relevant?

Although the ICH Q3A and Q3B guidelines establish reporting and qualification thresholds, there was a regulatory gap when new impurities appeared or their levels increased after marketing authorization. This document provides updated criteria and promotes more scientific and proportionate approaches.

## Main takeaways

### Addresses regulatory gaps

Complements ICH Q3A and Q3B by providing guidance when new impurities emerge, or levels increase post-authorization.

### Risk-based qualification

Introduces a structured, tiered assessment approach based on toxicological relevance.

### Animal testing reduction

Prioritizes alternative methods in line with the 3Rs principles.

### Acceptable Level (AL)

Establishes AL derivation from toxicological data (e.g. NOAEL, BMDL) with defined adjustment factors.

### Strategic assessment tools

- Read-across with analogous compounds
- Threshold of Toxicological Concern (TTC)
- In silico methods ((Q)SAR, modelling)
- In vitro tests and New Approach Methodologies (NAMs)

### Qualification criteria clarified

- Impurities that are relevant metabolites in non-clinical or clinical studies
- Impurities structurally related to the API without new toxicophores

### Limited in vivo testing

New animal studies should be exceptional and preferably conducted with the isolated impurity.

## Who is affected?

- Marketing Authorization Holders managing post-approval changes
- Sponsors developing new medicinal products
- Quality, CMC, and toxicology teams involved in impurity control strategies

## What MAHs should do now

**1. Review impurity strategies against the new EMA qualification framework.**

**2. Implement integrated risk assessments combining toxicology, structure, and exposure data.**

**3. Prepare robust justifications for AL, TTC, and read-across approaches.**

**4. Strengthen NAM capabilities to support non-animal testing strategies.**

**5. Anticipate regulatory expectations for post-approval changes and development programs.**
---
Source: https://qbdgroup.com/en/regulatory-updates/ema-framework-for-the-qualification-of-non-mutagenic-impurities — © QbD Group. Quote freely with attribution and a link back.